about
Cancer classification using the Immunoscore: a worldwide task forceThe significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patientsThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursThe circadian clock in cancer development and therapyDo inflammatory markers predict prognosis in patients with synchronous colorectal cancer?Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasisMutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valueSystemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients.Trial Watch: Adoptive cell transfer immunotherapy.Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged SwordExtended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101.The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: comparison with ImmunoscoreInflammation in uveal melanomaIntralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursMiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancerPrognostic potential of an immune score based on the density of CD8+ T cells, CD20+ B cells, and CD33+/p-STAT1+ double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients.Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapyIntratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Can immuno-oncology offer a truly pan-tumour approach to therapy?Tumor microenvironment and myeloid-derived suppressor cells.Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence.Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications.Metastatic melanoma cells evade immune detection by silencing STAT1.GBP-1 acts as a tumor suppressor in colorectal cancer cells.Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.Immune effects of bevacizumab: killing two birds with one stoneToward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapyThe immune score as a new possible approach for the classification of cancer.Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue.NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.
P2860
Q21245495-6F8D676D-D94C-4F72-B671-59E8AC61AEFFQ26738665-DE92E7FD-DA10-4E89-8C06-E518D711AF09Q27022789-EA42862C-2DC8-4C06-96EF-5D768C897843Q27026489-B8066D6D-6D84-477E-9F1E-A3B70BD434BBQ28390451-69B506B6-B1AA-446E-AB1F-1F3EC47EEE39Q33627043-DCE8C2EF-0DB5-4E51-A04E-7810EA19D51BQ34110125-8D2136AD-3748-4F0E-BE97-5BE403CADC07Q34755943-A7AD1AF0-F1B8-4B2F-A525-96136EB2F9ABQ35927872-F0A109AB-257B-4F1D-990D-551D8BAA173DQ36057432-5865768E-4865-46B0-8C90-9A5D0321902FQ36062936-8A1760F2-DF42-49DB-AC67-7AAB2AFF9D0FQ36114649-8725D5A8-91BE-4A73-9D15-473728E470FCQ36183887-A33EDA04-3F1D-4FB0-B796-A6AB561A2234Q36515365-0AF31367-3E56-48E3-9960-865358A49458Q36546411-9A5334D2-4079-47E1-938D-5BB558E7B83CQ36615048-08E7A761-CC33-495F-941C-6DBAF9E5CFF2Q36638606-6867F6A8-C72A-4848-908E-D2F1AFAC4E3AQ37190321-634AE27C-EF52-47D5-9CA9-33C5266D9E09Q37233874-C692F16B-5494-4E23-9645-E67A5281AC28Q37402113-A9177D50-C8B4-495D-969B-8D276257CE39Q37543402-B28E9152-D941-4CAB-B298-8D1396CED3B7Q37637243-A3EC1D44-5160-4BC3-AE92-5BDA374D6969Q38025696-43FAC74D-FFE7-4509-81AA-03F80D22ECF9Q38037493-E8E67752-8B13-4E3E-9504-4EBF76C65EA5Q38067642-1106BEE0-FE53-4756-91AA-832E38D68A45Q38197678-8D380865-BBFC-48FA-9849-EFE221EF7445Q38435397-389C744E-9724-4351-A8F8-7D754F98861BQ38515225-10D85F50-D0AE-42C2-A3FD-37AFF4C7EE7FQ38792725-7B49CB96-0635-4368-8228-6422C9BEE436Q38869738-6ACF7673-5E38-4FF4-9B6E-023C2FC92356Q38908693-CAABEEE5-0A36-4E93-AE81-06A01B081E6CQ39264514-58406009-A0D5-41CC-A6DD-2529C7A855D5Q39313889-85A6C9CC-5114-4603-B4C9-E82E180EBA21Q39409268-4E9D36D9-0B51-464D-B1D2-F9AD57F42D1CQ40423175-71C555F7-1703-4D1B-92AD-DF348900EB25Q41401879-0B9AF537-6074-4CD4-A67E-20F43AAD8196Q42180889-B516D35B-A2BD-4419-AB51-B704082C499CQ42539190-51E3ABBC-F5E8-48B2-B880-1C52CA984536Q42603820-117F967C-A4FA-4C9C-A2BF-3F2884250E09Q45723785-1838CD14-110B-4CF6-AF1C-253E95E86599
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Tumor immunosurveillance in human cancers.
@ast
Tumor immunosurveillance in human cancers.
@en
Tumor immunosurveillance in human cancers.
@nl
type
label
Tumor immunosurveillance in human cancers.
@ast
Tumor immunosurveillance in human cancers.
@en
Tumor immunosurveillance in human cancers.
@nl
prefLabel
Tumor immunosurveillance in human cancers.
@ast
Tumor immunosurveillance in human cancers.
@en
Tumor immunosurveillance in human cancers.
@nl
P2093
P2860
P1476
Tumor immunosurveillance in human cancers.
@en
P2093
Bernhard Mlecnik
Franck Pagès
Gabriela Bindea
P2860
P2888
P356
10.1007/S10555-011-9270-7
P577
2011-03-01T00:00:00Z
P5875
P6179
1041474080